Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 10/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | MC4R | P32245 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | PTK2B | Q14289 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.85 |
| ▸ | CLK1 | P49759 | 1/20 | 0.85 |
| ▸ | GSK3A | P49840 | 1/20 | 0.85 |
| ▸ | GSK3B | P49841 | 1/20 | 0.85 |
| ▸ | TP53 | P04637 | 2/20 | 0.82 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2909677 | 0.85 | MAPT (0.79) | GAAMAPTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL23494034 | 0.81 | MAPT (0.74) | GAAMAPTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL31307855 | 0.81 | MAPT (0.74) | GAAMAPTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL528999 | 0.81 | MAPT (0.78) | GAAMAPTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL13692627 | 0.81 | MAPT (0.70) | GAAMAPTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL2913762 | 0.81 | MAPT (0.68) | GAAMAPTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL2909576 | 0.81 | GAA (0.71) | GAAMAPTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL20435773 | 0.81 | MEN1 (0.88) | GAAMAPTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL2913530 | 0.80 | GAA (0.67) | GAAMAPTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL31393501 | 0.80 | MAPT (1.00) | GAAMAPTSMN1; SMN2TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070148185-A1 | Novel therapeutic target for protozoal diseases | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY | 2007-06-28 | — | — | US | claimed |
| WO-2007047579-A2 | A NOVEL THERAPEUTIC TARGET FOR PROTOZOAL DISEASES | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| US-20090221624-A1 | 4-AMINOQUINOLINE COMPOUNDS FOR TREATING VIRUS-RELATED CONDITIONS | OLIVO PAUL D | 2009-09-03 | — | — | US | disclosed |
| US-20090221624-A1 | 4-AMINOQUINOLINE COMPOUNDS FOR TREATING VIRUS-RELATED CONDITIONS | OLIVO PAUL D | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221624-A1 | 4-AMINOQUINOLINE COMPOUNDS FOR TREATING VIRUS-RELATED CONDITIONS | MAVS, EIF2AK2, SARS1 | GAA 125/4885MAPT 1032/4885SMN1; SMN2 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.